Figure 2.
Incidence (A) and risk difference (B) of virological failure (VF) between dolutegravir monotherapy (DTG-m) and combined antiretroviral therapy (cART).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.